Daxor Corporation
350 Fifth Avenue, Suite 7120
New York
New York
10118
United States
Tel: 212-244-0555
Fax: 212-244-0806
Website: http://www.daxor.com/
Email: webmaster@daxor.com
323 articles about Daxor Corporation
-
New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion
4/16/2024
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces two new studies validating the clinical benefits of blood volume analysis (BVA) as a more precise measurement of congestion in ambulatory heart failure (HF) patients.
-
DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™)
4/15/2024
Daxor Corporation announces today it will be exhibiting at the MedAxiom CV Transforum Spring’24 Conference being held at the Atlanta Marriott Marquis in GA, from April 18-20, 2024.
-
Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital
4/10/2024
Daxor Corporation, the global leader in blood volume measurement technology announces the purchase of Daxor’s BVA-100™ at a 450-bed teaching hospital in the greater Chicago area.
-
Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24
4/1/2024
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the American College of Cardiology (ACC.24) at the Georgia World Congress Center in Atlanta, GA, April 6 – 8, 2024.
-
Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics
3/25/2024
Daxor Corporation announces today it has entered into a definitive agreement to acquire exclusive and worldwide rights and intellectual property to manufacture from its existing supplier for Volumex and Megatope from privately-held Iso-Tex Diagnostics, Inc.
-
Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024
3/22/2024
Daxor Corporation announces an investor call to be held on Monday, March 25, 2024, at 4:00 p.m. ET.
-
Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023
3/18/2024
Daxor Corporation, the global leader in blood volume measurement technology, announces the filing of its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2023.
-
Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base
3/11/2024
Daxor Corporation, the global leader in blood volume measurement technology announces the expansion of blood volume analysis in three new hospitals through new analyzer purchases, and the utilization of Daxor’s ezBVA Lab service.
-
Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor’s Unique Clinical Utility for Heart Failure Patients
3/8/2024
Daxor Corporation, the global leader in blood volume measurement technology, announces new data from Duke University Medical Center validating the benefits of blood volume analysis in optimizing individualized therapy for heart failure patients with impaired renal function.
-
Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference
2/26/2024
Daxor Corporation today announces it will be exhibiting at the Technology and Heart Failure Therapeutics Conference (THT), which brings together the world’s leading experts in heart failure innovations at the Westin Boston Seaport in Boston, Massachusetts March 4-6, 2024.
-
Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions
2/12/2024
Daxor Corporation, the global leader in blood volume measurement technology announces two significant new customer transactions with Daxor’s BVA-100™ in January, marking a strong start to 2024.
-
Daxor Corporation Closes Q4 2023 with Growth in New Sales to Hospital Systems and Increased Utilization of its BVA-100® Blood Volume Diagnostic Across the U.S. at Existing Accounts
2/7/2024
Daxor Corporation announces the expansion of blood volume analysis through new analyzer purchases and the utilization of Daxor’s ezBVA Lab service.
-
Daxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual Meeting
1/29/2024
Daxor Corporation today announces it will be exhibiting at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Mid-Winter and American College Nuclear Medicine (ACNM) Annual Meeting at the Hilton Orlando Lake Buena Vista in Orlando, FL, February 1-3, 2024.
-
Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2024 Critical Care Congress
1/16/2024
Daxor Corporation announces it will be exhibiting at the Society for Critical Care Medicine 2024 Critical Care Congress at the Phoenix Convention Center in Phoenix, AZ from January 21 through January 23, 2024.
-
Daxor Awarded Additional New Patent for Smart Blood Volume Guidance Technology to Improve Treatment and Outcomes
1/9/2024
Daxor Corporation announces that the United States Patent and Trademark Office has issued the company a second patent, safeguarding a distinctive clinical guidance system for blood volume management.
-
Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer
1/2/2024
Daxor Corporation today announces it has submitted its next-generation blood volume analyzer - Daxor BVA - to the U.S. Food and Drug Administration (FDA) via the 510(k)/CLIA-waiver dual submission pathway.
-
New Randomized Controlled Trial Demonstrates the Efficacy of Daxor’s BVA Guided-Care in Heart Failure Patients
11/13/2023
Daxor Corporation announces the presentation of data from a Phase I National Institute of Health sponsored randomized control trial from two Veterans Affairs Medical Centers, validating treatment decisions guided by the Company’s BVA-100® diagnostic blood test benefitted patients with acute decompensated heart failure.
-
Daxor Corporation Awarded New Patent for Remote Monitoring of Blood Volume
11/9/2023
Daxor Corporation announces that Daxor was recently granted a patent for a system to provide remote blood volume monitoring after initial testing with Daxor BVA-100® diagnostic.
-
Expert Panelists Advocate Use of Daxor’s Technology to Optimize Treatment at Heart Failure Society of America Annual Scientific Meeting
10/13/2023
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces that experts recommend the use of blood volume analysis (BVA) to guide optimal treatment in heart failure patient at two Scientific Sessions held during the Heart Failure Society of America Annual Scientific Meeting on October 8th & 9th, 2023, at the Huntington Convention Center in Cleveland, OH.
-
New Data from Banner University Medicine Demonstrating Effectiveness of BVA-100® Use in Ambulatory Heart Failure Patients Presented at Heart Failure Society of America Annual Scientific Meeting
10/11/2023
Daxor Corporation, the global leader in blood volume measurement technology, announces new data from Banner University Medicine Advanced Heart Failure Clinic in Phoenix, AZ validating the benefits of the Company’s BVA-100 diagnostic blood test for ambulatory patients with advanced heart failure.